

Prescription Monitoring Program Advisory Council State of Louisiana

January 7, 2009

MINUTES

A meeting of the Prescription Monitoring Program (PMP) Task Force scheduled to meet on Wednesday, January 7, 2009 at the office of the Louisiana Board of Pharmacy, 5615 Corporate Blvd., Suite 8-E, Baton Rouge, Louisiana 70808, convened at 1:05 p.m. to consider the following:

A G E N D A

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items
4. Consideration of Minutes from Prior Meeting – October 29, 2008
5. Progress Report on Implementation Process
6. Review of Implementation
7. Demonstration of RxSentry® Program
8. Opportunity for Public Comment
9. Calendar Notes
10. Adjourn

Advisory Council representatives/designees present: Dr. Burdine (Medical Society), Erin Cormier (State Board of Dentistry), Sophia Thomas (LA Association of Nurse Practitioners), Louis LaJarza (DEA), Brenda Lands (DHH), Carl W. Aron (LABP), Alfred L. Gaudet (LSBME), Julie Wilkinson (LPA), Major Adam White (State Police), JJ Williams (DA's Association), Rep. H. Bernard LeBas (LA House of Representatives), Peggy Griener (LABN), Major Mittendorf (Academy of Physician Assistants), Dr. Joseph Comaty (Board of Psychologists), Colonel Pete Tufaro (Sheriff's Association), Mary Staples (NACDS).

Others present: Malcolm J. Broussard (LABP), Kathleen Gaudet (LABP), Carlos M. Finalet, III (LABP), Sarah Blakey (LABP), Joe Fontenot (LABP), Colonel Chad Clark (St. Bernard Sheriff's Office), Warren Rivera (DEA), Steve Cannizaro (SBSO), Dennis Lynch (DEA/JPSO), Andy Soileau (LIPA), Phyllis Perron (LPA), Marty McKay, Brad Cook (LPA), Jennifer Guero (LSBN).

Consideration of Minutes from October 29, 2008 Meeting

Minutes were approved by consensus of the Council.

Progress Report on Implementation Process

To date, the program has collected 5.1 million record transactions from June 1, 2008 to present. Malcolm Broussard explained that one dispensed transaction is considered one record for our database's purposes.

Representative LeBas asked which pharmacy dispensing software vendors are not in compliance. Joe Fontenot, PMP Program Manager, explained that the Board does not have jurisdiction over those vendors, only the dispenser pharmacies in those instances.

Review of Implementation

The Board is responsible for 3 components under its PMP Program:

- (1) Controlled Dangerous Substance Program education
- (2) Continuing education program
- (3) Evaluation component – some suggested performance measures for the program. These are elements we can extract from the program (attached as *Exhibit A*); Mr. Broussard requested input and suggestions from Council members on additional performance measures.

Of the 16,000 prescribers and dispensers only 600 have gone through the access approval process.

Col. Tufaro asked if the Board will send those procedures to all law enforcement agencies. Mr. Broussard explained that the Board is relying on each Advisory Council member to inform its own constituents of those procedures.

Demonstration of RxSentry® Program

Mr. Fontenot demonstrated the RxSentry® Program.

The PMP laws do not require anyone to use the information in the database. Several Council members suggested a regulatory mandate to require access before any controlled drug is dispensed. Ms. Staples stated that mandating access is problematic because several chain stores prohibit web access at the pharmacy site.

Rep. LeBas suggested mandatory program completion for all newly credentialed dispensers. Mr. Aron pointed out the PMP Program allows for prescribers or dispensers to more easily exercise corresponding responsibility to determine valid medical treatment.

Issues:

Guidance – Mr. Fontenot asked each licensing board provide guidance to its licensees on proper action when a potential violation of doctor shopping laws is discovered. DEA requested it be contacted. Col. Tufaro also requested notifying the appropriate regional/local law enforcement agency.

Drugs of concern – Ms. Staples requested ‘drugs of concern’ to be scheduled as controlled drugs to better facilitate the reporting process. Her concern is with a pharmacy’s ability to capture nonscheduled drug data for the program. Mr. Aron said State Police has tried to have Soma (Carisoprodol) listed as a CIV in the past, but has not been successful. Mr. Broussard also suggested looking at the option of listing them as CVI (where drugs are scheduled at the state level when they are not federally scheduled).

JJ Williams suggested revisiting whether veterinarians should be subjected to reporting due to their prescribing of several controlled drugs and potential drugs of concern.

Opportunity for Public Comment

Dennis Lynch (DEA/JPSO) – if he requests information from the PMP Program will the Board provide that information by paper or software in the format desired? Mr. Fontenot suggested he can provide an Excel spreadsheet with that information.

Calendar Notes

The next meeting is tentatively scheduled for April 8, 2009, starting at 1:00 p.m.
The remaining meeting dates for 2009 are: July 8th and October 14th.

The Council adjourned at 3:00 p.m.

I certify that the foregoing are true and accurate minutes.

Malcolm J. Broussard
Executive Director
Louisiana Board of Pharmacy

Prepared by: Carlos M. Finalet, III, General Counsel, Louisiana Board of Pharmacy